Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial - OncLive

OncLive

Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial OncLive Alectinib (Alecensa) reduced the risk of disease progression or death compared with crizotinib (Xalkori) as a frontline treatment for patients with ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III ALEX trial. and more »

from Health - Google News http://ift.tt/2o1AiMo